+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antibody Drug Conjugates Market (5th Edition), 2019-2030

  • ID: 4850761
  • Report
  • 615 Pages
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • 3SBio
  • BioGeneration Ventures
  • Eli Lilly
  • Jennison Associates
  • Osage University Partners
  • SpringWorks Therapeutics
  • MORE

With six approved and marketed drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), antibody drug conjugates (ADCs) have become recognized as a potent class of targeted therapeutic agents catering to oncology and hematological diseases markets. The success of such conjugated products can be attributed to their ability to effectively identify and eliminate disease-associated cells / pathogens, while limiting off-target toxicities. Presently, ADCs are considered a part of mainstream healthcare regimens, having generated significant enthusiasm within the medical science community across the world.

The growing popularity and therapeutic potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed / granted; the cumulative patent count has increased from 1,395 in 2009 to over 16,500 in the first half of 2019. With more than 200 ADCs in clinical / preclinical stages of development, the industry is gradually shifting from relying on conventional technologies to newer and more robust approaches to conjugate such complex biomolecules. Over the years, a number of well-funded start-ups / small companies, offering novel conjugation technologies, more potent warheads and advanced linker technologies, have been established. In fact, multiple licensing agreements / collaborations have been inked in the past few years between drug developers and technology providers to advance the development of pipeline ADC candidates.  

Using ADCs in combination with other drug / therapy classes is an emerging concept and multiple companies are evaluating their proprietary ADC candidates in combination with other established therapeutic classes, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies. In addition, several other companies have introduced certain novel types of conjugated drug molecules; example of such companies include Bicycle Therapeutics (bicycle drug conjugate), BlinkBio (tunable drug conjugates), Cellectar Biosciences (phospholipid drug conjugate), Centrose (extracellular drug conjugate), Esperance Pharmaceuticals (peptide conjugate) and Nordic Nanovector (radionucleotide conjugate). We expect the ADC therapeutics market to grow at a healthy rate in the mid to long-term, driven by the introduction of new combination therapies involving ADCs, innovative ADC development and conjugation technologies, applications beyond oncology and the expansion of existing marketing authorizations to newer geographies across the world.

Scope of the Report

The ‘Antibody Drug Conjugates Market (5th Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of ADCs, providing information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency.
  • Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.
  • An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
  • A list of key opinion leaders (KOLs) within this domain, featuring detailed 2X2 matrices to assess the relative experience of key individuals, who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field. It also includes a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. In addition, it presents an analysis assessing the credibility and (relative) level of expertise of different KOLs, based on number of publications, number of citations, number of clinical trials, number of affiliations and strength of professional network (based on information available on LinkedIn).
  • An insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved in drug development efforts based on a singular target and geographical distribution of associated clinical trials.
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing ADCs.
  • An in-depth analysis of the various patents that have been filed / granted related to ADCs till May 2019. It includes information on key parameters, such as patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April), highlighting various important parameters, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.
  • An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch, including a timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products.
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®.
  • An assessment of the various therapeutics that are being evaluated in combination with ADCs. The study also presents the likely evolution of these therapeutics across different indications.
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations; in addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. It also includes an analysis of the different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • An elaborate discussion on various factors that form the basis for the pricing of ADC products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years.
  • A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
  • A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving ADCs, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for ADCs, over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates and expected prices of such products, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030. The report includes potential sales forecasts of ADCs that are currently marketed or are in late stages of development. Additionally, it provides forecasts of the overall ADCs market, wherein the current and upcoming opportunity is segmented across [A] type of payload (MMAE, DM4, camptothecin, DM1, MMAF and others), [B] type of linker (VC, Sulfo-SPDB, SMCC, VA, hydrazone linker and others), [C] target indications (breast cancer, lymphoma (HL, NHL, ALCL), leukemia (AML, ALL), urothelial cancer, lung cancer (NSCLC, SCLC), ovarian cancer and others), [D] target antigens (CD30, HER2, CD22, CD33 and others (HER4, TROP-2, EGFR, FOLR1, MSLN, CD142, CD79b, DLL3, CD37, Nectin – 4, LIV-1, c-MET, BCMA, CD25, CD19 and ENPP3)), [E] technology providers (Seattle Genetics, ImmunoGen, StemCentRx, Immunomedics and others), and [F] key geographies (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of these novel therapeutics and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Alan Burnett (Professor, School of Medicine, Cardiff University)
  • Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • John Burt (Chief Executive Officer, Abzena)
  • Jennifer L. Mitcham (Director,  SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Healthcare)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio
  • BioGeneration Ventures
  • Eli Lilly
  • Jennison Associates
  • Osage University Partners
  • SpringWorks Therapeutics
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Anticancer Therapy
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibody-Based Anticancer Therapies
3.5. Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
3.8. Pharmacokinetic Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Excretion

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADC Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Indication
4.2.3. Analysis by Line of Treatment
4.2.4. Analysis by Dosing Regimen
4.2.5. Analysis by Type of Therapy
4.2.6. Analysis by Target Antigen
4.2.7. Analysis by Antibody Origin
4.2.8. Analysis by Antibody Isotype
4.2.9. Analysis by Type of Linker
4.2.10. Analysis by Type of Payload / Warhead
4.2.11. Key Technology Providers
4.2.12. Discontinued Drugs
4.3. ADC Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Indication
4.3.3. Analysis by Target Antigen
4.3.4. Key Players: Analysis by Number of ADC Therapeutics
4.4. ADC Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Geographical Location
4.4.4. Logo Landscape: Analysis by Size and Target Indication
4.5. Novel Drug Conjugates

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. AbbVie
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Pipeline Overview
5.2.3.1. Rovalpituzumab Tesirine / ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
5.2.3.2. Teliso-V / Telisotuzumab Vedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
5.2.4. Recent Developments and Future Outlook
5.3. Astellas Pharma
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Pipeline Overview
5.3.3.1. Enfortumab Vedotin
5.3.3.1.1. Drug Overview
5.3.3.1.2. Mechanism of Action
5.3.3.1.3. Clinical Development Status
5.3.3.1.4. Key Clinical Trial Results
5.3.3.2. ASG16-M8F
5.3.3.2.1. Drug Overview
5.3.3.2.2. Mechanism of Action
5.3.3.2.3. Clinical Development Status
5.3.3.2.4. Key Clinical Trial Results
5.3.4. Recent Developments and Future Outlook
5.4. AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and Future Outlook
5.5. Daiichi Sankyo
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Pipeline Overview
5.5.3.1. Trastuzumab deruxtecan / DS-8201a / DS 8201
5.5.3.1.1. Drug Overview
5.5.3.1.2. Mechanism of Action
5.5.3.1.3. Clinical Development Status
5.5.3.1.4. Key Clinical Trial Results
5.5.4. Recent Developments and Future Outlook
5.6. ImmunoGen
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Pipeline Overview
5.6.3.1. IMGN853 / Mirvetuximab soravtansine
5.6.3.1.1. Drug Overview
5.6.3.1.2. Mechanism of Action
5.6.3.1.3. Clinical Development Status
5.6.3.1.4. Key Clinical Trial Results
5.6.4. Recent Developments and Future Outlook
5.7. Immunomedics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Pipeline Overview
5.7.3.1. IMMU-130
5.7.3.1.1. Drug Overview
5.7.3.1.2. Mechanism of Action
5.7.3.1.3. Clinical Development Status
5.7.3.1.4. Key Clinical Trial Results
5.7.4. Recent Developments and Future Outlook
5.8. Pfizer
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Pipeline Overview
5.8.3.1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
5.8.3.1.1. Drug Overview
5.8.3.1.2. Mechanism of Action
5.8.3.1.3. Clinical Development Status
5.8.3.1.4. Key Clinical Trial Results
5.8.3.2. MYLOTARG™ / Gemtuzumab Ozogamicin
5.8.3.2.1. Drug Overview
5.8.3.2.2. Mechanism of Action
5.8.3.2.3. Clinical Development Status
5.8.3.2.4. Key Clinical Trial Results
5.8.4. Recent Developments and Future Outlook
5.9. Roche / Genentech
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Pipeline Overview
5.9.3.1. KADCYLA®
5.9.3.1.1. Drug Overview
5.9.3.1.2. Mechanism of Action
5.9.3.1.3. Clinical Development Status
5.9.3.1.4. Key Clinical Trial Results
5.9.3.2. RG-7596
5.9.3.2.1. Drug Overview
5.9.3.2.2. Mechanism of Action
5.9.3.2.3. Clinical Development Status
5.9.3.2.4. Key Clinical Trial Results
5.9.4. Recent Developments and Future Outlook
5.10. Seattle Genetics
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Pipeline Overview
5.10.3.1. ADCETRIS®
5.10.3.1.1. Drug Overview
5.10.3.1.2. Mechanism of Action
5.10.3.1.3. Clinical Development Status
5.10.3.1.4. Key Clinical Trial Results
5.10.3.2. SGN- LIV1A
5.10.3.2.1. Drug Overview
5.10.3.2.2. Mechanism of Action
5.10.3.2.3. Clinical Development Status
5.10.3.2.4. Key Clinical Trial Results
5.10.4. Recent Developments and Future Outlook
5.11. Synthon
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Pipeline Overview
5.11.3.1. SYD985 / Trastuzumab Duocarmazine
5.11.3.1.1. Drug Overview
5.11.3.1.2. Mechanism of Action
5.11.3.1.3. Clinical Development Status
5.11.3.1.4. Key Clinical Trial Results
5.11.4. Recent Developments and Future Outlook
5.12. Other Companies
5.12.1. Bayer HealthCare
5.12.1.1. Company Overview
5.12.1.2. Financial Information
5.12.1.3. Pipeline Overview
5.12.1.4. Recent Developments and Future Outlook
5.12.2. Biotest Pharmaceuticals
5.12.2.1. Company Overview
5.12.2.2. Financial Information
5.12.2.3. Pipeline Overview
5.12.2.4. Recent Developments and Future Outlook

6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADC Therapeutics for Leukemia / Lymphoma
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADC Therapeutics for Multiple Myeloma
6.3. Solid Tumors
6.3.1. Lung Cancer
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADC Therapeutics for Lung Cancer
6.3.2. Breast Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADC Therapeutics for Breast Cancer
6.3.3. Ovarian Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADC Therapeutics for Ovarian Cancer
6.3.4. Bladder Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADC Therapeutics for Bladder Cancer
6.3.5. Colorectal Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADC Therapeutics for Colorectal Cancer
6.3.6. Prostate Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADC Therapeutics for Prostate Cancer
6.3.7. Gastric Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADC Therapeutics for Prostate Cancer

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Methodology
7.3. Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
7.3.1. Geographical Distribution of Key Opinion Leaders
7.3.1.1. Experts on ADCETRIS®
7.3.1.2. Experts on KADCYLA®
7.3.1.3. Experts on MYLOTARG™
7.3.1.4. Experts on Other ADCs
7.4. Prominent Key Opinion Leaders (KOLs)
7.5. KOL Benchmarking: Publisher versus Third Party Scoring (ResearchGate Score)
7.6. Most Active Key Opinion Leaders
7.6.1. Profile: KOL A (Celgene)
7.6.2. Profile: KOL B (Western Regional Medical Center)
7.6.3. Profile: KOL C (MedStar Washington Hospital Center)
7.6.4. Profile: KOL D (Cancer Institute and Hospital)
7.6.5. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
7.6.6. Profile: KOL F (Hopital Tenon)
7.6.7. Profile: KOL G (Cleveland Clinic)

8. TARGET COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Competitiveness Analysis: Key Clinical Targets for ADCs
8.3.1. Four-Dimensional Bubble Analysis
8.3.2 Five-Dimensional Spider Web Analysis
8.4. Competitiveness Analysis: Key Preclinical Targets for ADCs
8.4.1. Two-Dimensional Scatter Plot Analysis

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. ADC Therapeutics: List of Partnerships and Collaborations
9.3.1 Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnerships
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. ADC Therapeutics: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. High Value Deals: Analysis by Year
10.3.4. Analysis by Type of Funding
10.3.5. Most Active Players
10.3.5.1. Analysis by Number of Funding Instances
10.3.5.2. Analysis by Amount Invested
10.4. Concluding Remarks

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. ADC Therapeutics: Patent Analysis
11.3.1. Analysis by Publication Year
11.3.2. Analysis by Geographical Location
11.3.3. Analysis by CPC Classification
11.3.4. Emerging Focus Areas
11.3.5. Analysis by Type of Industry
11.3.6. Leading Players: Analysis by Number of Patents
11.4. ADC Therapeutics: Patent Benchmarking Analysis (Industry Players)
11.4.1. Analysis by Patent Characteristics
11.4.2. Analysis By Geographical Location
11.5. ADC Therapeutics: Patent Valuation Analysis

12. ACADEMIC GRANTS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: List of Academic Grants
12.3.1. Analysis by Number of Grants
12.3.2. Analysis by Type of Grant
12.3.3. Analysis by Grant Amount
12.3.4. Analysis by Focus Area
12.3.5. Analysis by Support Period
12.4. Leading Organizations: Analysis by Number of Grants
12.5. Analysis by Type of Recipient Organization
12.6. Analysis by Administering Institute Center
12.7. Analysis by Funding Institute Center
12.8. Key Project Leaders: Analysis By Number of Grants

13. KEY COMMMERCIALIZATION STRATEGIES
13.1. Chapter Overview
13.2. Successful Drug Launch Strategy: ROOTS Framework
13.3. Successful Drug Launch Strategy: Product Differentiation
13.4. Common Commercialization Strategies Adopted Based on Development Stage of Product
13.5. Approved Molecules For ADCs
13.5.1. ADCETRIS®
13.5.2. KADCYLA®
13.5.3. MYLOTARG™
13.5.4. BESPONSA®
13.5.5. LUMOXITI™
13.5.5. POLIVY™
13.6. Key Commercialization Strategies Adopted by Companies Developing ADCs
13.6.1. Strategies Adopted Before Drug Approval
13.6.1.2. Collaboration with Internal Stakeholders and Pharmaceutical Firms
13.6.2. Strategies Adopted During / Post Drug Approval
13.6.2.1. Geographical Expansion
13.6.2.2. Participation in Global Events
13.6.2.3. Awareness Through Product Websites
13.6.2.4. Collaboration with Internal Stakeholders and Pharmaceutical Firms
13.7. Concluding Remarks

14. PROMOTIONAL ANALYSIS
14.1. Chapter Overview
14.2. Channels Used for Promotional Campaigns
14.3. Summary of Product Website Analysis
14.4. Summary of Patient Brochure and Informative Downloads
14.5. ADCETRIS®: Promotional Analysis
14.5.1. Product Website Analysis
14.5.1.1. Messages for Healthcare Professionals
14.5.1.2. Messages For Patients
14.5.2. Patient Support Services and Informative Downloads
14.5.3. Other Promotional Activities
14.5.3.1. Presence in Conferences
14.6. KADCYLA®: Promotional Analysis
14.6.1. Product Website Analysis
14.6.1.1. Messages for Healthcare Professionals
14.6.1.2. Messages for Patients
14.6.2. Patient Support Services and Informative Downloads
14.6.3. Other Promotional Activities
14.6.3.1. Presence in Conferences
14.7. MYLOTARG™: Promotional Analysis
14.7.1. Product Website Analysis
14.7.1.1. Messages for Healthcare Professionals
14.7.1.2. Messages for Patients
14.7.2. Patient Support Services and Informative Downloads
14.7.3. Other Promotional Activities
14.7.3.1. Presence in Conferences
14.8. BESPONSA®: Promotional Analysis
14.8.1. Product Website Analysis
14.8.1.1. Messages for Healthcare Professionals
14.8.1.2. Messages for Patients
14.8.2. Patient Support Services and Informative Downloads
14.8.3. Other Promotional Activities
14.8.3.1. Presence in Conferences
14.9. LUMOXITI™: Promotional Analysis
14.9.1. Product Website Analysis
14.9.1.1. Messages for Healthcare Professionals
14.9.1.2. Messages for Patients
14.9.2. Patient Support Services and Informative Downloads
14.9.3. Other Promotional Activities
14.9.3.1. Presence in Conferences
14.10. POLIVY™: Promotional Analysis
14.10.1. Product Website Analysis
14.10.1.1. Messages for Healthcare Professionals
14.10.1.2. Messages for Patients
14.10.2. Patient Support Services and Informative Downloads
14.10.3. Other Promotional Activities
14.10.3.1. Presence in Conferences

15. COMBINATION THERAPIES
15.1. Chapter Overview
15.2. Combination Therapy: History of Development
15.3. FDA-approved Combination Therapies in Oncology
15.4. Combination Therapy: FDA Guidelines
15.4.1. Combinations of Marketed Drugs
15.4.2. Combinations of Marketed Drugs with New Molecular Entities
15.4.3. Combinations of New Molecular Entities
15.5. Combination Therapies: ADCs
15.5.1. Completed / Ongoing Clinical Studies of ADCs
15.5.1.1. Analysis by Type of Therapy
15.5.2. Completed / Ongoing Clinical Studies of ADC-based Combination Therapies
15.5.2.1. Analysis by Highest Phase of Development
15.5.2.2. Analysis by Current Trial Status
15.5.2.3. Analysis by Type of Combination
15.5.2.4. Analysis by Indication and Type of Combination

16. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
16.1. Chapter Overview
16.2. First Generation ADC Technologies
16.3. Second Generation ADC Technologies
16.3.1. Cysteine and Selenocysteine Engineering
16.3.2. Unnatural Amino Acid Engineering
16.3.3. Amino-Terminal Engineered Serine
16.4. Third Generation ADC Technologies
16.4.1. Enzyme-Assisted Ligation Approaches
16.4.2. Glycan Remodeling Approaches
16.4.3. Ligation at Fab Nucleotide-Binding Site
16.4.4. Cysteine Rebridging
16.4.5. Preventing / Limiting Retro-Michael Drug Deconjugation
16.5. Evolutionary Analysis of Conjugation Technologies

17. ASSESSMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
17.1. Chapter Overview
17.2. ADCs and Non-Clinical Studies
17.3. ICH S9 Guidelines
17.4. Investigational New Drug (IND)-Enabling Study Designs
17.4.1. Example Case: KADCYLA®
17.5. Toxicities in Animal Models
17.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
17.7. Other Key Considerations for Study Design

18. COST PRICE ANALYSIS
18.1. Chapter Overview
18.2. Factors Contributing Towards the High Price of ADC Therapeutics
18.3. ADC Therapeutics Market: Pricing Models
18.3.1. On the Basis of Associated Costs
18.3.2. On the Basis of Competition
18.3.3. On the Basis of Patient Segment
18.4. Reimbursement Considerations for ADC Therapeutics

19. CASE STUDY: CONTRACT MANUFACTURING OF ADC
19.1. Chapter Overview
19.2. Key Steps for ADC Manufacturing
19.3. Technical Concerns Related to ADC Manufacturing
19.4. Challenges Associated with Supply Chain and Method Transfer
19.5. Limitations of In-House Manufacturing
19.6. Investments in ADC Manufacturing Capability Expansions
19.7. Collaborations Established for ADC Manufacturing
19.8. Growing Demand for Contract Manufacturing
19.9. Emergence of Start-Ups Offering Contract Services
19.10. CMOs with Linker Manufacturing Capabilities
19.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
19.12. CMOs with Conjugation Capabilities
19.13. ADC One Stop Shops

20. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS
20.1. Chapter Overview
20.1.1. Advantages of Companion Diagnostics
20.1.2. Disadvantages of Companion Diagnostics
20.2. Companion Diagnostics for ADC Therapeutics
20.3. ADC Therapeutics: List of Companion Diagnostics
20.3.1. Analysis by Type of Target
20.3.2. Analysis by Type of Cancer Indication
20.4. Concluding Remarks

21. MARKET FORECAST AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Scope and Limitations
21.3. Forecast Methodology
21.4. Overall ADC Therapeutics Market
21.4.1. ADC Therapeutics Market: Distribution by Target Indication
21.4.2. ADC Therapeutics Market: Distribution by Type of Linker
21.4.3. ADC Therapeutics Market: Distribution by Type of Payload
21.4.4. ADC Therapeutics Market: Distribution by Target Antigen
21.4.5. ADC Therapeutics Market: Distribution by Geography
21.4.6. ADC Therapeutics Market: Distribution by Technology Providers
21.5. ADC Therapeutics Market: Individual Drug Sales Forecasts
21.5.1. ADCETRIS® / Brentuximab Vedotin
21.5.1.1. Target Patient Population
21.5.1.2. Sales Forecast
21.5.2. KADCYLA® / Ado-trastuzumab Emtansine
21.5.2.1. Target Patient Population
21.5.2.2. Sales Forecast
21.5.3. MYLOTARG™ / Gemtuzumab Ozogamicin
21.5.3.1. Target Patient Population
21.5.3.2. Sales Forecast
21.5.4. BESPONSA® / Inotuzumab Ozogamicin
21.5.4.1. Target Patient Population
21.5.4.2. Sales Forecast
21.5.5. LUMOXITI™
21.5.5.1. Target Patient Population
21.5.5.2. Sales Forecast
21.5.6. POLIVYTM / Polatuzumab vedotin-piiq / RG7596
21.5.6.1. Target Patient Population
21.5.6.2. Sales Forecast
21.5.7. ASG-22ME / Enfortumab Vedotin
21.5.7.1. Target Patient Population
21.5.7.2. Sales Forecast
21.5.8. BAT8001
21.5.8.1. Target Patient Population
21.5.8.2. Sales Forecast
21.5.9. DS-8201a / DS 8201 / Trastuzumab Deruxtecan
21.5.9.1. Target Patient Population
21.5.9.2. Sales Forecast
21.5.10. IMMU-132 / Sacituzumab Govitecan
21.5.10.1. Target Patient Population
21.5.10.2. Sales Forecast
21.5.11. IMGN853 / Mirvetuximab Soravtansine
21.5.11.1. Target Patient Population
21.5.11.2. Sales Forecast
21.5.12. lpituzumab TesirineRova-T / Rova
21.5.12.1. Target Patient Population
21.5.12.2. Sales Forecast
21.5.13. SYD985 / Trastuzumab Duocarmazine
21.5.13.1. Target Patient Population
21.5.13.2. Sales Forecast
21.5.14. ABBV-399 / Teliso-V / Telisotuzumab Vedotin
21.5.14.1. Target Patient Population
21.5.14.2. Sales Forecast
21.5.15. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine
21.5.15.1. Target Patient Population
21.5.15.2. Sales Forecast
21.5.16. ADCT-402 / Loncastuximab Tesirine
21.5.16.1. Target Patient Population
21.5.16.2. Sales Forecast
21.5.17. AGS 16M8F / AGS 16C3F
21.5.17.1. Target Patient Population
21.5.17.2. Sales Forecast
21.5.18. AVID100
21.5.18.1. Target Patient Population
21.5.18.2. Sales Forecast
21.5.19. BAY 94-9343
21.5.19.1. Target Patient Population
21.5.19.2. Sales Forecast
21.5.20. GSK 2857916 / Anti-BCMA ADC
21.5.20.1. Target Patient Population
21.5.20.2. Sales Forecast
21.5.21. HuMax-TF-ADC / Tisotumab Vedotin
21.5.21.1. Target Patient Population
21.5.21.2. Sales Forecast
21.5.22. IMGN529 / Debio 1562 / Naratuximab Emtansine
21.5.22.1. Target Patient Population
21.5.22.2. Sales Forecast
21.5.23. IMMU-130 / Sacituzumab Govitecan
21.5.23.1. Target Patient Population
21.5.23.2. Sales Forecast
21.5.24. RC48
21.5.24.1. Target Patient Population
21.5.24.2. Sales Forecast
21.5.25. SGN-LIV1A / Ladiratuzumab Vedotin
21.5.25.1. Target Patient Population
21.5.25.2. Sales Forecast

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks

23. CONCLUSION
23.1. Chapter Overview
23.2. Key Takeaways

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Abzena
24.2.1. Company Snapshot
24.2.2. Interview Transcript: John Burt, Chief Executive Officer
24.3. Ajinomoto Bio-Pharma Services
24.3.1. Company Snapshot
24.3.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager
24.4. BSP Pharmaceuticals
24.4.1. Company Snapshot
24.4.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
24.5. Catalent Pharma Solutions
24.5.1. Company Snapshot
24.5.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates, and Stacy McDonald, Group Product Manager
24.6. Cardiff University
24.6.1. Company Snapshot
24.6.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
24.7. Cerbios-Pharma
24.7.1. Company Snapshot
24.7.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
24.8. Eisai
24.8.1. Company Snapshot
24.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer
24.9. Lonza
24.9.1. Company Snapshot
24.9.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development
24.10. NBE-Therapeutics
24.10.1. Company Snapshot
24.10.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer
24.11. Oxford BioTherapeutics
24.11.1. Company Snapshot
24.11.2. Interview Transcript: Christian Rohlff, Chief Executive Officer and Founder
24.12. Pierre Fabre
24.12.1. Company Snapshot
24.12.2. Interview Transcript: Christian Bailly, Director of CDMO
24.13. Piramal Healthcare
24.13.1. Company Snapshot
24.13.2. Interview Transcript: Mark Wright, Site Head, Grangemouth
24.14. Synaffix
24.14.1. Company Snapshot
24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development
24.15. Syndivia
24.15.1. Company Snapshot
24.15.2. Interview Transcript: Sasha Koniev, Chief Executive Officer and Co-Founder
24.16. Anonymous, Director, Business Development, Leading CMO
24.17. Anonymous, Chief Executive Officer, Leading CMO

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1. Evolution of Anticancer Treatments
Figure 3.2. Cancer Treatment: Types of Surgeries
Figure 3.3. Cancer Treatment: Types of Radiation Therapies
Figure 3.4. Cancer Treatment: Types of Chemotherapies
Figure 3.5. Components of an ADC
Figure 3.6. Comparative Analysis of Pharmacokinetic Properties of ADCs: Dosing Regimen, Cmax and T1/2
Figure 4.1. ADC Therapeutics Clinical Pipeline: Distribution by Phase of Development
Figure 4.2. ADC Therapeutics Clinical Pipeline: Distribution by Indication
Figure 4.3. ADC Therapeutics Clinical Pipeline: Distribution by Line of Treatment
Figure 4.4. ADC Therapeutics Clinical Pipeline: Distribution by Dosing Regimen
Figure 4.5. ADC Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Figure 4.6. ADC Therapeutics Clinical Pipeline: Distribution by Target Antigen
Figure 4.7. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Origin
Figure 4.8. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Isotype
Figure 4.9. ADC Therapeutics Clinical Pipeline: Distribution by Type of Linker
Figure 4.10. ADC Therapeutics Clinical Pipeline: Distribution by Type of Payload / Warhead
Figure 4.11. ADC Therapeutics Clinical Pipeline: Distribution by Key Technology Providers
Figure 4.12. ADC Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Figure 4.13. ADC Therapeutics Preclinical Pipeline: Distribution by Indication
Figure 4.14. ADC Therapeutics Preclinical Pipeline: Distribution by Target Antigen
Figure 4.15. ADC Therapeutics Preclinical Pipeline: Distribution by Key Players
Figure 4.16. ADC Therapeutics Developer Landscape: Distribution by Year of Establishment
Figure 4.17. ADC Therapeutics Developer Landscape: Distribution by Size of Developer
Figure 4.18. ADC Therapeutics Developer Landscape: Distribution by Geographical Location
Figure 4.19. ADC Therapeutics Developer Landscape: Logo Landscape
Figure 5.1. AbbVie: Annual Revenues, 2014 – H1 2019 (USD Billion)
Figure 5.2. Rovalpituzumab Tesirine / ROVA-T: Registered Clinical Trials
Figure 5.3. Teliso-V / Telisotuzumab Vedotin / ABBV-399: Registered Clinical Trials
Figure 5.4. Astellas Pharma: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Figure 5.5. Enfortumab Vedotin: Registered Clinical Trials
Figure 5.6. ASG16-M8F: Registered Clinical Trials
Figure 5.7. AstraZeneca: Annual Revenues, 2014– H1 2019 (USD Billion)
Figure 5.8. LUMOXITI™: Registered Clinical Trials
Figure 5.9. Daichi Sankyo: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Figure 5.10. Trastuzumab Deruxtecan / DS-8201a / DS 8201: Registered Clinical Trials
Figure 5.11. ImmunoGen: Annual Revenues, 2014–Q1 2019 (USD Million)
Figure 5.12. IMGN853 / Mirvetuximab Soravtansine: Registered Clinical Trials
Figure 5.13. Immunomedics: Annual Revenues 2014-2018 (USD Million)
Figure 5.14. IMMU-130: Registered Clinical Trials
Figure 5.15. Pfizer: Annual Revenues, 2014–H1 2019 (USD Billion)
Figure 5.16. BESPONSA®: Registered Clinical Trials
Figure 5.17. MYLOTARG™: Registered Clinical Trials
Figure 5.18. Roche: Annual Revenues, 2014–H1 2019 (USD Billion)
Figure 5.19. KADCYLA®: Registered Clinical Trials
Figure 5.20. RG-7596: Registered Clinical Trials
Figure 5.21. Seattle Genetics: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 5.22. ADCETRIS®: Registered Clinical Trials
Figure 5.23. SGN-LIV1A: Registered Clinical Trials
Figure 5.24. Synthon: Annual Revenues, 2014-2018 (USD Million)
Figure 5.25. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Figure 5.26. Bayer Healthcare: Annual Revenues, 2014– H1 2019 (EUR Billion)
Figure 5.27. BAY 94-9343: Registered Clinical Trials
Figure 5.28. Biotest Pharmaceuticals: Revenue, 2014-H1 2019 (EUR Million)
Figure 5.29. BT-062: Registered Clinical Trials
Figure 6.1. Leukemia: Disease Classification
Figure 6.2. Leukemia: Global Epidemiological Distribution
Figure 6.3. Lymphoma: Global Epidemiological Distribution
Figure 6.4. Multiple Myeloma: Global Epidemiological Distribution
Figure 6.5. Lung Cancers: Disease Classification
Figure 6.6. Lung Cancer: Global Epidemiological Distribution
Figure 6.7. Breast Cancer: Global Epidemiological Distribution
Figure 6.8. Ovarian Cancer: Global Epidemiological Distribution
Figure 6.9. Bladder Cancer: Global Epidemiological Distribution
Figure 6.10. Colorectal Cancer: Global Epidemiological Distribution
Figure 6.11. Prostate Cancer: Global Epidemiological Distribution
Figure 6.12. Gastric Cancer: Global Epidemiological Distribution
Figure 7.1. KOL Analysis: Distribution by Type of Organization
Figure 7.2. KOL Analysis: Geographical Distribution of Principal Investigators
Figure 7.3. KOL Analysis: Dot-Plot of Principal Investigators
Figure 7.4. KOL Benchmarking: Publisher versus Third Party Scoring
Figure 7.5. KOL Analysis: Most Prominent Key Opinion Leaders
Figure 9.1. Partnerships and Collaborations: Cumulative Trend by Year, 2011-2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2015 and Post 2015
Figure 9.4. Most Active Players: Distribution by Number of Partnerships
Figure 9.5. Partnerships and Collaborations: Regional Distribution
Figure 9.6. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 10.1. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer, 2011-2019
Figure 10.2. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2011-2019
Figure 10.3. Funding and Investment Analysis: Cumulative Amount Invested by Year, 2011-2019 (USD Million)
Figure 10.4. Funding and Investment Analysis: Average Amount Invested per Year, 2011-2019 (USD Million)
Figure 10.5. Funding and Investment Analysis: High Value Deals, 2011-2019
Figure 10.6. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2011-2019
Figure 10.7. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2011-2019 (USD Million)
Figure 10.8. Most Active Players: Distribution by Number of Funding Instances
Figure 10.9. Most Active Players: Distribution by Amount Invested
Figure 10.10. Funding and Investment Summary, 2011-2019 (USD Million)
Figure 11.1. Patent Analysis: Distribution by Type of Patent
Figure 11.2. Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2019
Figure 11.3. Patent Analysis: Distribution by Geographical Location
Figure 11.4. Patent Analysis: Distribution by CPC Symbol
Figure 11.5. Patent Analysis: Emerging Focus Areas
Figure 11.6. Patent Analysis: Distribution by Type of Applicant
Figure 11.7. Leading Industry Players: Distribution by Number of Patents
Figure 11.8. Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.9. Patent Analysis: Benchmarking by Patent Characteristics
Figure 11.10. Patent Analysis: Benchmarking by Number of International Patents
Figure 11.11. Patent Analysis: Distribution of Patents Age (2000-2019)
Figure 11.12. Patent Analysis: Distribution of Patents by Geography (2014-2019)
Figure 11.13. Patent Analysis: Valuation Analysis
Figure 12.1. Academic Grant Analysis: Distribution by Number of Grants Awarded
Figure 12.2. Academic Grant Analysis: Distribution by Type of Grant
Figure 12.3. Academic Grant Analysis: Year-Wise Distribution by Grant Amount (USD Million)
Figure 12.4. Academic Grant Analysis: Distribution by Focus Area
Figure 12.5. Academic Grant Analysis: Distribution by Support Period
Figure 12.6. Academic Grant Analysis: Year-Wise Distribution across Leading Grant Types
Figure 12.7. Academic Grant Analysis: Distribution by States in the US
Figure 12.8. Leading Recipient Organizations: Distribution by Number of Grants
Figure 12.9. Leading Recipient Organizations: Distribution by Amount Awarded
Figure 12.10. Academic Grant Analysis: Distribution by Type of Recipient Organization
Figure 12.11. Academic Grant Analysis: Distribution by Administering Institute Center
Figure 12.12. Academic Grant Analysis: Distribution by Funding Institute Center
Figure 12.13. Key Project Leaders: Distribution by Number of Grants
Figure 13.1. Successful Drug Launch Strategy: ROOTS Framework
Figure 13.2. Successful Drug Launch Strategy: Product Differentiation
Figure 13.3. Common Commercialization Strategies Adopted Based on Development Stage of Product
Figure 13.4. Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Developing ADCs
Figure 13.5. Approval of Drugs in Multiple Geographies: Historical Timeline
Figure 13.6. Approved ADC Therapeutics: Promotional Activities through Product Websites
Figure 14.1. Promotional / Marketing Strategy: Product Website Analysis
Figure 14.2. Promotional / Marketing Strategy: Patient Brochure and Unique Features
Figure 14.3. Promotional / Marketing Strategy: Informative Downloads
Figure 14.4. ADCETRIS® Website Analysis: Messages for Healthcare Professionals
Figure 14.5. ADCETRIS® Website Analysis: Messages for Patients
Figure 14.6. ADCETRIS® Website Analysis: Patient Support Program
Figure 14.7. KADCYLA® Website Analysis: Messages for Healthcare Professionals
Figure 14.8. KADCYLA® Website Analysis: Messages for Patients
Figure 14.9. KADCYLA® Website Analysis: Patient Support Program
Figure 14.10. MYLOTARG™ Website Analysis: Messages for Healthcare Professionals
Figure 14.11. MYLOTARG™ Website Analysis: Messages for Patients
Figure 14.12. MYLOTARG™ Website Analysis: Patient Assistance Services
Figure 14.13. MYLOTARG™ Website Analysis: Pfizer Oncology Together Program
Figure 14.14. BESPONSA® Website Analysis: Messages for Healthcare Professionals
Figure 14.15. BESPONSA® Website Analysis: Messages for Patients
Figure 14.16. BESPONSA® Website Analysis: Patient Assistance Services
Figure 14.17. BESPONSA® Website Analysis: Pfizer Oncology Together Program
Figure 14.18. LUMOXITI™ Website Analysis: Messages for Healthcare Professionals
Figure 14.19. LUMOXITI™ Website Analysis: Messages for Patients
Figure 14.20. LUMOXITI™ Website Analysis: Patient Support Program
Figure 14.21. POLIVY™ Website Analysis: Messages for Healthcare Professionals
Figure 14.22. POLIVY™ Website Analysis: Messages for Patients
Figure 14.23. POLIVY™ Website Analysis: Patient Support Program
Figure 15.1. ADCs Clinical Studies: Distribution by Type of Therapy
Figure 15.2. ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 15.3. ADCs Combination Therapy Clinical Studies: Distribution by Current Trial Status
Figure 15.4. ADCs Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination
Figure 15.5. ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
Figure 16.1. ADC Platforms: Technological Evolution
Figure 16.2. ADC Conjugation Platforms: Technology Landscape
Figure 17.1. First in Human Dose Calculation: Dose Escalation using BSA Conversion
Figure 17.2. Relationship between Dose-Limiting Toxicities and ADC Warhead
Figure 17.3. Maximum Tolerated Dose (MTD: Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
Figure 18.1. ADC Therapeutics: Relative Share of Individual Processes in the Cost of Production
Figure 18.2. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fees) (%)
Figure 18.3. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fees) (%)
Figure 18.4. ADC Therapeutics: Pricing Model Based on Patient Segment
Figure 18.5. ADC Therapeutics: Pricing Model Based on Reimbursement Approvals
Figure 19.1. ADC Contract Manufacturers: Distribution by Services Offered
Figure 20.1. Advantages of Companion Diagnostics
Figure 20.2. Companion Diagnostics: Distribution by Type of Target
Figure 20.3. Companion Diagnostics: Distribution by Type of Indication
Figure 21.1. Overall ADC Therapeutics Market, 2019-2030 (USD Billion)
Figure 21.2. ADC Therapeutics Market: Distribution by Target Indication, 2019, 2025 and 2030 (USD Billion)
Figure 21.3. ADC Therapeutics Market): Distribution by Type of Linker, 2019, 2025 and 2030 (USD Billion)
Figure 21.4. ADC Therapeutics Market: Distribution by Type of Payload, 2019, 2025 and 2030 (USD Billion)
Figure 21.5. ADC Therapeutics Market: Distribution by Type of Target Antigen, 2019, 2025 and 2030 (USD Billion)
Figure 21.6. ADC Therapeutics Market: Distribution by Geographical Region, 2019, 2025 and 2030 (USD Billion)
Figure 21.7. ADC Therapeutics Market: Distribution by Technology Providers, 2019, 2025 and 2030 (USD Billion)
Figure 21.8. ADCETRIS® Sales Forecast, till 2030 (USD Million)
Figure 21.9. KADCYLA® Sales Forecast, till 2030 (USD Million)
Figure 21.10. MYLOTARG™ Sales Forecast, till 2030 (USD Million)
Figure 21.11. BESPONSA® Sales Forecast, till 2030 (USD Million)
Figure 21.12. LUMOXITI™ Sales Forecast, till 2030 (USD Million)
Figure 21.13. POLIVYTM Sales Forecast, till 2030 (USD Million)
Figure 21.14. ASG-22ME / Enfortumab Vedotin Sales Forecast, till 2030: Base Scenario (USD Million)
Figure 21.15. BAT8001 Sales Forecast, till 2030 (USD Million)
Figure 21.16. DS-8201a / DS 8201 / Trastuzumab Deruxtecan Sales Forecast, till 2030 (USD Million)
Figure 21.17. IMMU-132 / Sacituzumab Govitecan Sales Forecast, till 2030 (USD Million)
Figure 21.18. IMGN853 / Mirvetuximab Soravtansine Sales Forecast, till 2030 (USD Million)
Figure 21.19. lpituzumab Tesirine Sales Forecast, till 2030 (USD Million)Rova-T / Rova
Figure 21.20. SYD985 / Trastuzumab Duocarmazine Sales Forecast, till 2030 (USD Million)
Figure 21.21. ABBV-399 / Teliso-V / Telisotuzumab Vedotin Sales Forecast, till 2030 (USD Million)
Figure 21.22. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine Sales Forecast, till 2030 (USD Million)
Figure 21.23. ADCT-402 / Loncastuximab Tesirine Sales Forecast, till 2030 (USD Million)
Figure 21.24. AGS 16M8F / AGS 16C3F Sales Forecast, till 2030 (USD Million)
Figure 21.25. AVID100 Sales Forecast, till 2030 (USD Million)
Figure 21.26. BAY 94-9343 Sales Forecast, till 2030 (USD Million)
Figure 21.27. GSK 2857916 / Anti-BCMA ADC Sales Forecast, till 2030 (USD Million)
Figure 21.28. HuMax-TF-ADC / Tisotumab Vedotin Sales Forecast, till 2030 (USD Million)
Figure 21.29. IMGN529 / Debio 1562 / Naratuximab Emtansine Sales Forecast, till 2030 (USD Million)
Figure 21.30. IMMU-130 / Sacituzumab Govitecan Sales Forecast, till 2030 (USD Million)
Figure 21.31. RC48 Sales Forecast, till 2030 (USD Million)
Figure 21.32. SGN-LIV1A / Ladiratuzumab Vedotin Sales Forecast, till 2030 (USD Million)
Figure 22.1. ADC Therapeutics: SWOT Analysis
Figure 22.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 23.1. Overall ADC Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)

List of Tables
Table 3.1. List of Approved Monoclonal Antibody Therapies
Table 3.2. Commonly Used Cytotoxins for ADC Therapeutics
Table 3.3. Occupational Exposure Limit Bands, Safebridge Consultants
Table 3.4. Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
Table 4.1. ADC Therapeutics: Clinical Pipeline
Table 4.2. ADC Therapeutics Clinical Pipeline: Components Specific Details
Table 4.3. ADC Therapeutics: Discontinued Drugs
Table 4.4. ADC Therapeutics: Preclinical Pipeline
Table 4.5. ADC Therapeutics: Developer Overview
Table 4.6. Novel Drug Conjugates
Table 5.1. AbbVie: Company Overview
Table 5.2. AbbVie ADC Therapeutics Pipeline
Table 5.3. Rova-T: Registered Clinical Trials
Table 5.4. Teliso-V: Registered Clinical Trials
Table 5.5. AbbVie: Future Outlook
Table 5.6. Astellas Pharma: Company Overview
Table 5.7. Astellas Pharma: ADC Therapeutics Pipeline
Table 5.8. ASG-22ME: Registered Clinical Trials
Table 5.9. ASG 16C3F: Registered Clinical Trials
Table 5.10. Astellas Pharma: Future Outlook
Table 5.11. AstraZeneca: Company Overview
Table 5.12. AstraZeneca: ADC Therapeutics Pipeline
Table 5.13. LUMOXITI™: Registered Clinical Trials
Table 5.14. AstraZeneca: Future Outlook
Table 5.15. Daichii Sankyo: Company Overview
Table 5.16. Daichii Sankyo: ADC Therapeutics Pipeline
Table 5.17. DS-8201a / DS 8201 / Trastuzumab Deruxtecan: Registered Clinical Trials
Table 5.18. Daichii Sankyo: Future Outlook
Table 5.19. ImmunoGen: Company Overview
Table 5.20. ImmunoGen: ADCs Pipeline
Table 5.21. IMGN853: Registered Clinical Trials
Table 5.22. IMGN529: Registered Clinical Trials
Table 5.23. ImmunoGen: Future Outlook
Table 5.24. Immunomedics: Company Overview
Table 5.25. Immunomedics: ADC Therapeutics Pipeline
Table 5.26. IMMU-130: Registered Clinical Trials
Table 5.27. Immunomedics: Future Outlook
Table 5.28. Pfizer: Company Overview
Table 5.29. Pfizer: ADCs Pipeline
Table 5.30. BESPONSA®: Registered Clinical Trials
Table 5.31. MYLOTARG™: Registered Clinical Trials
Table 5.32. Pfizer: Future Outlook
Table 5.33. Roche / Genentech: Company Overview
Table 5.34. Roche / Genentech: ADC Therapeutics Pipeline
Table 5.35. KADCYLA®: Registered Clinical Trials
Table 5.36. RG-7596: Registered Clinical Trials
Table 5.37. Roche / Genentech: Future Outlook
Table 5.38. Seattle Genetics: Company Overview
Table 5.39. Seattle Genetics: ADC Therapeutics Pipeline
Table 5.40. ADCETRIS®: Registered Clinical Trials
Table 5.41. SGN-CD19A: Registered Clinical Trials
Table 5.42. Seattle Genetics: Future Outlook
Table 5.43. Synthon: Company Overview
Table 5.44. Synthon: ADC Therapeutics Pipeline
Table 5.45. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Table 5.46. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Table 5.47. Synthon: Future Outlook
Table 5.48. Bayer Healthcare: Company Overview
Table 5.49. Bayer Healthcare: ADC Therapeutics Pipeline
Table 5.50. BAY 94-9343: Registered Clinical Trials
Table 5.51. Bayer Healthcare: Future Outlook
Table 5.52. Biotest Pharmaceuticals: Company Overview
Table 5.53. Biotest Pharmaceuticals: ADC Therapeutics Pipeline
Table 5.54. BT-062: Registered Clinical Trials
Table 5.55. Biotest Pharmaceuticals: Future Outlook
Table 6.1. Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 6.2. Leukemia: List of Marketed Targeted Therapeutics
Table 6.3. Lymphoma: List of Marketed Targeted Therapeutics
Table 6.4. ADC Therapeutics for Leukemia and Lymphoma
Table 6.5. Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 6.6. ADC Therapeutics for Multiple Myeloma
Table 6.7. Lung Cancer: List of Marketed Targeted Therapeutics
Table 6.8. ADC Therapeutics for Lung Cancer
Table 6.9. Breast Cancer: List of Marketed Targeted Therapeutics
Table 6.10. ADC Therapeutics for Breast Cancer
Table 6.11. Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 6.12. ADC Therapeutics for Ovarian Cancer
Table 6.13. Bladder Cancer: List of Marketed Targeted Therapeutics
Table 6.14. ADC Therapeutics for Bladder Cancer
Table 6.15. Colorectal Cancer: List of Marketed Targeted Therapeutics
Table 6.16. ADC Therapeutics for Colorectal Cancer
Table 6.17. Prostate Cancer: List of Marketed Targeted Therapeutics
Table 6.18. ADC Therapeutics for Prostate Cancer
Table 6.19. Gastric Cancer: List of Marketed Targeted Therapeutics
Table 6.20. ADC Therapeutics for Gastric Cancer
Table 7.1. KOL Analysis: List of Principal Investigators
Table 7.2. KOL Analysis: List of Universities and Hospitals
Table 7.3. KOL Analysis: Publisher Proprietary Scoring System
Table 7.4. Profile: KOL A (Celgene)
Table 7.5. Profile: KOL B (Western Regional Medical Center)
Table 7.6. Profile: KOL C (MedStar Washington Hospital Center)
Table 7.7. Profile: KOL D (Cancer Institute and Hospital)
Table 7.8. Profile: KOL E (Comprehensive Cancer Centers of Nevada)
Table 7.9. Profile: KOL F (Hopital Tenon)
Table 7.10. Profile: KOL G (Cleveland Clinic)
Table 9.1. ADC Therapeutics: Partnerships and Collaborations, 2011-2019
Table 10.1. ADC Therapeutics: Funding and Investments, 2011-2019
Table 10.2. ADC Therapeutics: Summary of Investments
Table 11.1. Patent: CPC Symbol Definitions
Table 11.2. Patent: Most Popular CPC Symbols
Table 11.3. Patent: List of Top CPC Symbols
Table 11.4. ADC Therapeutics: Summary of Patent Benchmarking Analysis
Table 11.5. Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 11.6. Leading Patents: Distribution by Relative Valuation
Table 12.1. ADC Therapeutics: List of Academic Grants, 2011-2019
Table 13.1. ADCETRIS®: Drug Overview
Table 13.2. KADCYLA®: Drug Overview
Table 13.3. MYLOTARG™: Drug Overview
Table 13.4. BESPONSA®: Drug Overview
Table 13.5. LUMOXITI™: Drug Overview
Table 13.6. POLIVY™: Drug Overview
Table 13.6. ADCETRIS®: List of Conferences Before Approval
Table 13.7. MYLOTARG™: List of Conferences Before Approval
Table 13.8. KADCYLA®: List of Conferences Before Approval
Table 13.9. BESPONSA®: List of Conferences Before Approval
Table 13.10. LUMOXITI™: List of Conferences Before Approval
Table 13.11. POLIVY™: List of Conferences Before Approval
Table 13.12. ADCETRIS®: List of Conferences Post Approval
Table 13.13. KADCYLA®: List of Conferences Post Approval
Table 13.13. Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
Table 15.1. FDA Approved Combination Therapies in Oncology, 2001-2019
Table 15.2. ADCs Combination Therapy Clinical Studies: Key Indications
Table 16.1. Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 15.2. Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 16.3. Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 16.4. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 16.5. Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 16.6. Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 16.7. Third Generation ADC Technologies: Cysteine Rebridging
Table 16.8. Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 17.1. ADCs Non-Clinical Studies: Safety Packages Required
Table 17.2. Single Dose Study of KADCYLA® in Cynomolgus Monkey
Table 17.3. ADCs: Dose Limiting Toxicities in Clinical Studies
Table 18.1. ADC Components: Information on Cost by Type of Linker
Table 18.2. ADC Component: Information on Cost by Type of Cytotoxin
Table 18.3. Price of Marketed ADCs
Table 18.4. Price of Marketed Targeted Drugs
Table 19.1. List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 19.2. List of HPAPI and Cytotoxic Drugs Manufacturing Service Providers
Table 19.3. Contract Manufacturers for ADCs: Geographical Distribution
Table 19.4. One Stop Shops for ADC Manufacturing: Information on Location of Manufacturing Facilities
Table 20.1. Companion Diagnostics: List of Available / Under Development Tests for ADCs
Table 21.1. ADC Therapeutics: Expected Launch Years
Table 21.2. ADCETRIS®: Target Patient Population
Table 21.3. KADCYLA®: Target Patient Population
Table 21.4. MYLOTARG™: Target Patient Population
Table 21.5. BESPONSA®: Target Patient Population
Table 21.6. LUMOXITI™: Target Patient Population
Table 21.7. POLIVYTM: Target Patient Population
Table 21.8. ASG-22ME / Enfortumab Vedotin: Target Patient Population
Table 21.9. BAT8001: Target Patient Population
Table 21.10. DS-8201a / DS 8201 / Trastuzumab Deruxtecan: Target Patient Population
Table 21.11. IMMU-132 / Sacituzumab Govitecan: Target Patient Population
Table 21.12. IMGN853 / Mirvetuximab Soravtansine: Target Patient Population
Table 21.13. lpituzumab Tesirine: Target Patient PopulationRova-T / Rova
Table 21.14. SYD985 / Trastuzumab Duocarmazine: Target Patient Population
Table 21.15. ABBV-399 / Teliso-V / Telisotuzumab Vedotin: Target Patient Population
Table 21.16. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine: Target Patient Population
Table 21.17. ADCT-402 / Loncastuximab Tesirine: Target Patient Population
Table 21.18. AGS 16M8F / AGS 16C3F: Target Patient Population
Table 21.19. AVID100: Target Patient Population
Table 21.20. BAY 94-9343: Target Patient Population
Table 21.21. GSK 2857916 / Anti-BCMA ADC: Target Patient Population
Table 21.22. HuMax-TF-ADC / Tisotumab Vedotin: Target Patient Population
Table 21.23. IMGN529 / Debio 1562 / Naratuximab Emtansine: Target Patient Population
Table 21.24. IMMU-130 / Sacituzumab Govitecan: Target Patient Population
Table 21.25. RC48: Target Patient Population
Table 21.26. SGN-LIV1A / Ladiratuzumab Vedotin: Target Patient Population
Table 25.1. ADC Therapeutics Clinical Pipeline: Distribution by Phase of Development
Table 25.2. ADC Therapeutics Clinical Pipeline: Distribution by Indication
Table 25.3. ADC Therapeutics Clinical Pipeline: Distribution by Line of Treatment
Table 25.4. ADC Therapeutics Clinical Pipeline: Distribution by Dosing Regimen
Table 25.5. ADC Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Table 25.6. ADC Therapeutics Clinical Pipeline: Distribution by Target Antigen
Table 25.7. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Origin
Table 25.8. ADC Therapeutics Clinical Pipeline: Distribution by Antibody Isotype
Table 25.9. ADC Therapeutics Clinical Pipeline: Distribution by Type of Linker
Table 25.10. ADC Therapeutics Clinical Pipeline: Distribution by Type of Payload / Warhead
Table 25.11. ADC Therapeutics Clinical Pipeline: Distribution by Key Technology Providers
Table 25.12. ADC Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Table 25.13. ADC Therapeutics Preclinical Pipeline: Distribution by Indication
Table 25.14. ADC Therapeutics Preclinical Pipeline: Distribution by Target Antigen
Table 25.15. ADC Therapeutics Preclinical Pipeline: Distribution by Key Players
Table 25.16. ADC Therapeutics Developer Landscape: Distribution by Year of Establishment
Table 25.17. ADC Therapeutics Developer Landscape: Distribution by Size of Developer
Table 25.18. ADC Therapeutics Developer Landscape: Distribution by Geographical Location
Table 25.19. AbbVie: Annual Revenues, 2014 – H1 2019 (USD Billion)
Table 25.20. Rovalpituzumab Tesirine / ROVA-T: Registered Clinical Trials
Table 25.21. Teliso-V / Telisotuzumab Vedotin / ABBV-399: Registered Clinical Trials
Table 25.22. Astellas Pharma: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Table 25.23. Enfortumab Vedotin: Registered Clinical Trials
Table 25.24. ASG16-M8F: Registered Clinical Trials
Table 25.25. AstraZeneca: Annual Revenues, 2014– H1 2019 (USD Billion)
Table 25.26. LUMOXITI™: Registered Clinical Trials
Table 25.27. Daichi Sankyo: Annual Revenues, 2014–Q1 2019 (JPY Billion)
Table 25.28. Trastuzumab Deruxtecan / DS-8201a / DS 8201: Registered Clinical Trials
Table 25.29. ImmunoGen: Annual Revenues, 2014–Q1 2019 (USD Million)
Table 25.30. IMGN853 / Mirvetuximab Soravtansine: Registered Clinical Trials
Table 25.31. Immunomedics: Annual Revenues 2014-2018 (USD Million)
Table 25.32. IMMU-130: Registered Clinical Trials
Table 25.33. Pfizer: Annual Revenues, 2014–H1 2019 (USD Billion)
Table 25.34. BESPONSA®: Registered Clinical Trials
Table 25.35. MYLOTARG™: Registered Clinical Trials
Table 25.36. Roche: Annual Revenues, 2014–H1 2019 (USD Billion)
Table 25.37. KADCYLA®: Registered Clinical Trials
Table 25.38. KADCYLA® Sales: 2014-H1 2019 (CHF Million)
Table 25.39. RG-7596: Registered Clinical Trials
Table 25.40. Seattle Genetics: Annual Revenues, 2014-H1 2019 (USD Million)
Table 25.41. ADCETRIS®: Registered Clinical Trials
Table 25.42. ADCETRIS® Sales: 2014- H1 2019 (USD Million)
Table 25.43. SGN-LIV1A: Registered Clinical Trials
Table 25.44. Synthon: Annual Revenues, 2014-2018 (USD Million)
Table 25.45. SYD985 / Trastuzumab Duocarmazine: Registered Clinical Trials
Table 25.46. Bayer Healthcare: Annual Revenues, 2014– H1 2019 (EUR Billion)
Table 25.47. BAY 94-9343: Registered Clinical Trials
Table 25.48. Biotest Pharmaceuticals: Revenue, 2014-H1 2019 (EUR Million)
Table 25.49. BT-062: Registered Clinical Trials
Table 25.50. Partnerships and Collaborations: Cumulative Trend by Year, 2011-2019
Table 25.51. Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.52. Partnerships and Collaborations: Distribution by Type of Partnership, 2011-2015 and Post 2015
Table 25.53. Most Active Players: Distribution by Number of Partnerships
Table 25.54. Partnerships and Collaborations: Regional Distribution
Table 25.55. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 25.56. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment of Developer, 2011-2019
Table 25.57. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2011-2019
Table 25.58. Funding and Investment Analysis: Cumulative Amount Invested by Year, 2011-2019 (USD Million)
Table 25.59. Funding and Investment Analysis: Average Amount Invested per Year, 2011-2019 (USD Million)
Table 25.60. Funding and Investment Analysis: High Value Deals, 2011-2019
Table 25.61. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2011-2019
Table 25.62. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2011-2019 (USD Million)
Table 25.63. Most Active Players: Distribution by Number of Funding Instances
Table 25.64. Most Active Players: Distribution by Amount Invested
Table 25.65. Funding and Investment Summary, 2011-2019 (USD Million)
Table 25.66. Patent Analysis: Distribution by Type of Patent
Table 25.67. Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2019
Table 25.68. Patent Analysis: Distribution by Geographical Location
Table 25.69. Patent Analysis: Distribution by Type of Applicant
Table 25.70. Patent Analysis: Distribution of Patents Age (2000-2019)
Table 25.71. Patent Analysis: Distribution of Patents by Geography (2014-2019)
Table 25.72. Academic Grant Analysis: Distribution by Number of Grants Awarded
Table 25.73. Academic Grant Analysis: Distribution by Type of Grant
Table 25.74. Academic Grant Analysis: Year-Wise Distribution by Grant Amount (USD Million)
Table 25.75. Academic Grant Analysis: Distribution by Support Period
Table 25.76. Academic Grant Analysis: Year-Wise Distribution across Leading Grant Types
Table 25.77. Leading Recipient Organizations: Distribution by Number of Grants
Table 25.78. Leading Recipient Organizations: Distribution by Amount Awarded
Table 25.79. Academic Grant Analysis: Distribution by Type of Recipient Organization
Table 25.80. Academic Grant Analysis: Distribution by Administering Institute Center
Table 25.81. Academic Grant Analysis: Distribution by Funding Institute Center
Table 25.82. Key Project Leaders: Distribution by Number of Grants
Table 25.83. ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 25.84. ADCs Combination Therapy Clinical Studies: Distribution by Current Trial Status
Table 25.85. ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
Table 25.86. ADC Therapeutics: Relative Share of Individual Processes in the Cost of Production
Table 25.87. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (Without Licensing Fees) (%)
Table 25.88. ADC Therapeutics: Distribution by Cost of Raw Material Required for the Manufacturing of ADC at Clinical Stage (With Licensing Fees) (%)
Table 25.89. ADC Contract Manufacturers: Distribution by Services Offered
Table 25.90. Companion Diagnostics for ADCs: Distribution by Type of Target
Table 25.91. Companion Diagnostics for ADCs: Distribution by Type of Indication
Table 25.92. Overall ADC Therapeutics Market, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Billion)
Table 25.93. ADC Therapeutics Market: Distribution by Target Indication, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.94. ADC Therapeutics Market: Distribution by Type of Linker, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.95. ADC Therapeutics Market: Distribution by Type of Payload, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.96. ADC Therapeutics Market: Distribution by Type of Target Antigen, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.97. ADC Therapeutics Market: Distribution by Geographical Region, Base, Conservative and Optimistic Scenarios, 2019, 2025 and 2030 (USD Billion)
Table 25.98. ADCETRIS® Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.99. KADCYLA® Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.100. MYLOTARG™ Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.101. BESPONSA® Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.102. LUMOXITI™ Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.103. POLIVYTM Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.104. ASG-22ME / Enfortumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.105. BAT8001 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.106. DS-8201a / DS 8201 / Trastuzumab Deruxtecan Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.107. IMMU-132 / Sacituzumab Govitecan Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.108. IMGN853 / Mirvetuximab Soravtansine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.109. lpituzumab Tesirine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.110. SYD985 / Trastuzumab Duocarmazine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.111. ABBV-399 / Teliso-V / Telisotuzumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.112. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.113. ADCT-402 / Loncastuximab Tesirine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.114. AGS 16M8F / AGS 16C3F Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.115. AVID100 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.116. BAY 94-9343 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.117. GSK 2857916 / Anti-BCMA ADC Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.118. HuMax-TF-ADC / Tisotumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.119. IMGN529 / Debio 1562 / Naratuximab Emtansine Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.120. IMMU-130 / Sacituzumab Govitecan Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.121. RC48 Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)
Table 25.122. SGN-LIV1A / Ladiratuzumab Vedotin Sales Forecast, Base, Conservative and Optimistic Scenarios, till 2030 (USD Million)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3SBio
  • BioGeneration Ventures
  • Eli Lilly
  • Jennison Associates
  • Osage University Partners
  • SpringWorks Therapeutics
  • MORE

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the ADC market in the short to mid-term and long term.

Chapter 3 provides a general introduction to ADCs. In this section, we have discussed, in detail, the concept of ADC, its various components, mechanisms of action and advantages over traditional targeted therapies. The chapter also presents a brief description of the absorption, distribution, metabolism and excretion (ADME) properties of the various ADCs that are under development.

Chapter 4 provides a comprehensive overview of the market landscape of ADCs that are either approved or under development. This chapter includes information on drug developer(s) and technology provider(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target antigen, type of linker, type of payload / warhead / cytotoxin, type of antibody, antibody origin, antibody isotype, type of therapy (monotherapy and combination therapy), combination drug (if being evaluated as combination therapy), target indication(s), line of treatment, route of administration and dosing frequency. The chapter also highlights the various ADCs that have been discontinued over the last few years.

Chapter 5 presents elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios; each profile features an overview of the company, its financial information (if available), detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and key clinical trial results) and an informed future outlook.

Chapter 6 identifies the most commonly targeted therapeutic indications and features brief descriptions of the ADC candidates being developed against them. It highlights the key epidemiological facts about the diseases and currently available treatment options, other than ADCs.

Chapter 7 provides an analysis of KOLs in the field of ADCs. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with the information related to the affiliated research institutes. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The credibility and (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on number of publications, number of citations, number of clinical trials, number of affiliations and extent of professional network.

Chapter 8 presents an insightful competitiveness analysis of biological targets, featuring a [A] three-dimensional bubble representation that highlights the targets that are being evaluated for ADC development, taking into consideration the number of lead molecules based on a particular target, phase of development of candidate therapies, number of clinical trials and number of target disease indications, and [B] a five-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including affiliated publications, grants received to support research on a particular target, number of industry players involved drug development efforts based on a singular target and geographical distribution of associated clinical trials.

Chapter 9 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between the players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of year of an agreement / partnership, the type of partnership model (R&D collaborations, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, clinical trial agreements, manufacturing agreements, mergers and acquisitions, manufacturing and service agreements, and others, companies involved, and regional distribution of the collaborations.

Chapter 10 presents details on various investments received by the start-ups / smaller companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, till July 2019, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 11 provides an in-depth patent analysis, presenting an overview on the filed / granted patents related to ADCs. For this analysis, we looked at the patents that have been published by various players, till May 2019. The analysis highlights key details and trends associated with these patents, including patent type, publication year, geographical location, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.

Chapter 12 provides information on the various grants that were awarded to research institutes conducting projects related to ADCs, between 2011 and 2019 (till April). The analysis also highlights important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, grant type, focus area, type of recipient organization, key project leaders, key regions and leading recipient organizations.

Chapter 13 presents an elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch and during / post launch. It also highlights an in-depth analysis and timeline representation of the key strategies adopted by drug developers for the commercialization of their proprietary products. In addition, it provides a general overview of the drugs considered for studying the strategies in detail.

Chapter 14 highlights the key promotional strategies that are being implemented by the developers of marketed products, including POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and ADCETRIS®. The promotional aspects covered in the chapter include details provided on the product website (including key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 15 features an overview of the various therapeutics being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapeutics across different therapeutic indications.

Chapter 16 provides a review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. In addition, it presents a review of the existing competition between various conjugation approaches that are available / under development.

Chapter 17 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it highlights possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.

Chapter 18 highlights our views on the various factors that must be taken into consideration while deciding the prices of ADC products. It features discussions on different models / approaches that pharmaceutical companies may choose to adopt while deciding the prices at which their ADC products can be marketed.

Chapter 19 provides details of the players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting their expansion plans and other agreements inked between companies.

Chapter 20 is a case study focused on the use of companion diagnostics in the field of ADCs. It provides a list of companies offering companion diagnostics for targets being targeted by ADCs, including information on their geographical location, affiliated biomarker, assay technique involved, target indication(s), the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidate(s) for which it is already available.

Chapter 21 features an elaborate discussion on the future commercial opportunity for the ADCs. It provides a comprehensive market forecast analysis of the molecules that are approved or are in late stages of clinical development taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely prices of the therapeutics. The chapter also presents a detailed market segmentation on the basis of [A] type of payload (MMAE, DM4, camptothecin, DM1, MMAF and others), [B] type of linker (VC, Sulfo-SPDB, SMCC, VA, hydrazone linker and others), [C] target indications (breast cancer, lymphoma (HL, NHL, ALCL), leukemia (AML, ALL), urothelial cancer, lung cancer (NSCLC, SCLC), ovarian cancer and others, [D] target antigens (CD30, HER2, CD22, CD33 and others (HER4, TROP-2, EGFR, FOLR1, MSLN, CD142, CD79b, DLL3, CD37, Nectin – 4, LIV-1, c-MET, BCMA, CD25, CD19 and ENPP3,)) [E] technology providers (Seattle Genetics, ImmunoGen, StemCentRx, Immunomedics and others), and [F] key geographies (North America, Europe and Asia Pacific).

Chapter 22 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.

Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 24 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Alan Burnett (Professor, School of Medicine, Cardiff University),     Aldo Braca (President and Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix),     Christian Bailly (Director of CDMO, Pierre Fabre), Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), John Burt (Chief Executive Officer, Abzena), Jennifer L. Mitcham (Director,  SMARTag ADCs and Bioconjugates, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), and Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics).

Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix, which contains the list of companies and organizations mentioned in the report.

Note: Product cover images may vary from those shown
5 of 5
  • 3SBio
  • 5AM Ventures
  • Abbott
  • AbbVie
  • AbGenomics
  • ABL Bio
  • Abraxis BioScience
  • Abzena
  • ACES Pharma
  • Actinium Pharmaceuticals
  • Adagene
  • ADC Bio
  • ADC Therapeutics
  • Adimab
  • Advanced Biotechnologies Venture Fund
  • Advanced Proteome Therapeutics
  • Advantage Capital
  • Advent Venture Partners
  • Aesica Pharmaceuticals
  • Agensys
  • Agilent Technologies
  • Agios Pharmaceuticals
  • Agno Pharma
  • Ajinomoto Althea
  • Alexion Pharmaceuticals
  • Alger
  • Algeta
  • Alkermes
  • Allos Therapeutics
  • Allozyne
  • Ally Bridge Group
  • Almac
  • Alphora Research
  • Alta Partners
  • Alteogen
  • Amatsigroup
  • Ambrx
  • Amgen
  • Amgen Ventures
  • Amoy Diagnostics
  • AMPAC Fine Chemicals
  • AMRI
  • Angiex
  • Antikor Biopharma
  • APO-T
  • Apricot Capital
  • Aptuit
  • Aravis
  • Arch Pharmalabs
  • ArrowMark Partners
  • Asana BioSciences
  • Ash Stevens
  • Astellas Pharma
  • AstraZeneca
  • Asymchem Laboratories
  • Atlas Venture
  • Atreca
  • Auven Therapeutics
  • Avalon Ventures
  • Avanthera
  • Avicenna Oncology
  • Baxter BioPharma Solutions
  • Bayer HealthCare
  • BDC Capital
  • BeiGene
  • BerGenBio
  • Beth Israel Deaconess Medical Center
  • Bicycle Therapeutics
  • BioAlta
  • Biogen Idec
  • BioGeneration Ventures
  • BioGenex
  • BioMed Valley Discoveries
  • BioSynthesis Pharma
  • Biotest
  • Bio-Thera Solutions
  • BioVectra
  • BlinkBio
  • Boehringer Ingelheim
  • BOM Capital
  • Bregua Corporation
  • Bristol-Myers Squibb
  • Bryllan
  • BSP Pharmaceuticals
  • BZL Biologics
  • Calculus Capital
  • California Institute for Regenerative Medicine
  • Cambrex
  • Cambridge Innovation Capital
  • Cambridge Major Laboratories
  • Canaan
  • Cancer Prevention and Research Institute of Texas  
  • Cancer Research UK
  • Capsugel
  • CARBOGEN AMCIS
  • Carb-X
  • Casdin Capital
  • Catalent
  • Cedarburg Pharmaceuticals
  • CEL Healthcare Fund
  • Celgene
  • Cellectar Biosciences
  • Cellerant Therapeutics
  • CellMosaic
  • Celltrion
  • Celon Laboratories
  • Centre for the Commercialization of Antibodies and Biologics
  • Centrose
  • Cerbios-Pharma
  • ChemCon
  • ChemSun Pharmaceutical
  • Children’s Hospital Los Angeles
  • Chugai Pharmaceutical
  • Cisbio
  • Clovis Oncology
  • Coldstream Laboratories
  • Concortis Biotherapeutics
  • CordenPharma
  • Corixa
  • Cormorant Asset Management
  • Creative Biolabs
  • Credit Suisse First Boston Next Fund
  • Crescendo Biologics
  • Crocker Ventures
  • Crystal Pharma
  • CSPC Pharmaceutical Group
  • CTI Life Sciences Fund
  • CureMeta
  • Custom Pharma Services
  • Cytogen
  • CytomX Therapeutics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • Debiopharm
  • Deerfield Management
  • DKFZ German Cancer Research Center
  • Dorizoe Lifesciences
  • DOTTIKON EXCLUSIVE SYNTHESIS
  • DSM Pharmaceuticals
  • Dyax
  • EirGen Pharma
  • Eisai
  • Elan Pharma
  • Elasmogen
  • Elder Pharmaceuticals
  • Eleven Biotherapeutics
  • Eli Lilly
  • Elusys Therapeutics
  • EMD Serono
  • Esperance Pharmaceuticals
  • Essex Bio-Technology
  • ETH Zurich
  • EUCODIS Bioscience
  • Evonik Industries
  • Excella
  • Exelixis
  • Farmabios
  • Femtogenix Ink
  • Ferring Pharmaceuticals
  • Fidelity Investments
  • FineTech Pharmaceutical
  • Fonds de solidarité FTQ
  • Forbius
  • Formex
  • Formosa Laboratories
  • Fortis Therapeutics
  • Fosun Pharma
  • Foundation Medicine
  • F-Prime Capital
  • GamaMabs Pharma
  • Genentech
  • Genmab
  • Gilead Sciences
  • Global Bio
  • Glycotope
  • Glykos
  • Goodwin Biotechnology
  • GP-Pharm
  • GSK
  • GT Biopharma
  • Halozyme Therapeutics
  • Hangzhou DAC Biotech
  • Harris Group
  • Haupt Pharma
  • HBM Healthcare Investments
  • HealthCap
  • Heidelberg Pharma
  • Helsinn Advanced Synthesis
  • Heraeus Deutschland
  • Hercules Capital
  • Hisun Pharmaceuticals
  • HOPU Investments
  • Human Genome Sciences
  • Humanwell Healthcare Group
  • Iconic Therapeutics
  • ICROM
  • Idifarma
  • IDT Australia
  • Igenica Biotherapeutics
  • Iksuda Therapeutics
  • ImClone Systems
  • ImmunoBiochem
  • ImmunoGen
  • Immunomedics
  • Indena
  • Innate   Pharma
  • Innovate UK
  • Intas Pharmaceuticals
  • Invenra
  • Invivoscribe
  • IONTAS
  • iProgen Biotech
  • IRIX Pharmaceuticals
  • Janssen Biotech
  • Jazz Pharmaceuticals
  • Jennison Associates
  • Jiangsu Hengrui Medicine
  • Johnson & Johnson
  • Johnson Matthey (Pharma Services)
  • Kairos Therapeutics
  • Karyopharm Therapeutics
  • Kite Pharma
  • KLUS Pharma
  • Kyongbo Pharmaceutical
  • Kyowa Hakko Kirin
  • Labochim
  • LegoChem Biosciences
  • Leica Biosystems
  • Levena Biopharma
  • Ligand Pharmaceuticals
  • Light Chain Bioscience
  • Lilly Asia Ventures
  • Lilly Ventures
  • LinXis
  • Longwood Fund
  • Lonza
  • Louisiana Fund
  • Lumira Ventures
  • MAB Discovery
  • MabPlex
  • MabSpace Biosciences
  • MabVax Therapeutics
  • MacroGenics
  • Magenta Therapeutics
  • Max Delbrück Center for Molecular Medicine
  • MediaPharma
  • Medichem
  • MedImmune
  • Meditope Biosciences
  • Medivation
  • Memorial Sloan Kettering Cancer Center
  • Menarini
  • Merck
  • Metrics Contract Services
  • Millennium Pharmaceuticals
  • MilliporeSigma
  • Minakem
  • Minomic
  • Mitsubishi Tanabe Pharma
  • MorphoSys
  • Morphotek
  • MS Ventures
  • MuseChem
  • NanoValent Pharmaceuticals
  • Natco Pharma
  • National Cancer Institute
  • National Cancer  Institute
  • NBE Therapeutics
  • NerPharMa
  • Nerviano Medical Sciences
  • New Enterprise Associates
  • Noonday Asset Management
  • Nordic Nanovector
  • Normon Laboratories
  • Northeast Securities Prosperity Healthcare Fund
  • Novartis
  • Novasep
  • Novo Holdings
  • Olon
  • Omni Chem
  • Oncolinx
  • Oncomatryx Biopharma
  • Onconova Therapeutics
  • Onyx Pharmaceuticals
  • OPKO Health
  • Orano Med
  • OrbiMed Advisors
  • Organon Teknika
  • Osage University Partners
  • OsoBio
  • Otsuka Pharmaceutical
  • Oxford BioTherapeutics
  • Oxford Finance
  • Palatin Technologies
  • Patheon
  • Paul Scherrer Institute
  • Penn Pharma
  • Perceptive Advisors
  • Pfanstiehl
  • Pfizer
  • Pharmaceutics International
  • Pharmacyclics
  • PharmaMar
  • Pharmatek
  • Philochem
  • Philogen
  • Pierre Fabre
  • Piramal Pharma Solutions
  • PolyTherics
  • Poniard Pharmaceuticals  
  • PPF Group
  • PrasFarma
  • ProBioGen
  • Procos
  • ProJect Pharmaceutics
  • ProLynx
  • ProQuest Investments
  • Puma Biotechnology
  • QIAGEN
  • QS Pharma
  • Quantum   Leap Investments
  • Rakuten Medical
  • Ramot
  • Recepta Biopharma
  • Recipharm
  • Redmile Group
  • Regeneron Pharmaceuticals
  • Regis Technologies
  • RemeGen
  • Research Corporation Technologies
  • Rho Ventures
  • Roche
  • Rock Springs Capital
  • Rottendorf Pharma
  • Royalty Pharma
  • Saltigo
  • Samsung Medical Center
  • Sandoz
  • Sanofi
  • Sanofi Genzyme
  • Sarah Cannon Research Institute
  • SBI Holdings
  • ScinoPharm
  • Scripps Research Institute
  • Seattle Genetics
  • Servier
  • Shanghai Fosun Pharmaceutical
  • Shanghai Fudan-zhangjiang Bio-Pharmaceutical
  • Shanghai Miracogen  
  • Shanghai Pharma
  • Shenogen Pharma
  • Shire
  • Siamab Therapeutics
  • Siegfried
  • Silicon Valley Bank
  • Sinopharm Capital
  • Skyline Ventures
  • Sorrento Therapeutics
  • SOTIO
  • Spectrum Pharmaceuticals
  • Spirogen
  • SpringWorks Therapeutics
  • SR One
  • STA Pharmaceutical
  • Starling Ventures
  • Stason Pharmaceuticals
  • Stemcentrx
  • Sun Pharmaceutical Industries
  • Sutro Biopharma
  • SV Life Sciences
  • Swedish Orphan Biovitrum
  • Symphogen
  • Synaffix
  • Syndivia
  • Syngene
  • Syntagon
  • Syntarga
  • Synthon Biopharmaceuticals
  • Synthorx
  • Taiho Oncology
  • TaiMed Biologics
  • Takeda Oncology
  • TBD-Biodiscovery
  • Tekla Healthcare Investors
  • Tekla Life Science Investors
  • Teruisi Pharmaceutical
  • TESARO
  • Teva Pharmaceutical Industries
  • The Column Group
  • The Scripps Research Institute
  • Themelios Ventures
  • Theratechnologies
  • Thermo Fisher Scientific
  • Thiel Capital
  • ThioLogics
  • Third Rock Ventures
  • Tolmar
  • TopoTarget
  • Tot Biopharm
  • TPG-Axon Capital
  • Triphase Accelerator
  • Triton Funds
  • Tubulis Technologies
  • UCB
  • Ultragenyx Pharmaceutical
  • Uman Pharma
  • United Therapeutics
  • University College  of London
  • University Medical Center Groningen
  • University of California
  • University of Freiburg
  • University of Georgia
  • University of Wisconsin Carbone Cancer Center
  • University  of Copenhagen
  • UPM Pharmaceuticals
  • Uquifa
  • Vaccinex
  • Valeant Pharmaceuticals
  • VelosBio
  • Venrock Healthcare Capital Partners
  • Ventures West
  • Verastem Oncology
  • Vertex Ventures
  • Visterra
  • VivaMab
  • Vivo Capital
  • VUAB Pharma
  • Watson Pharmaceuticals
  • Wellington Management Company
  • Wild Ventures
  • Wild  Family Office
  • WS Investments
  • WT Investment Advisors Fund
  • WuXi Biologics
  • WuXi PharmaTech
  • Xintela
  • Y Biologics
  • York University
  • Yuhan Corporation
  • Zhejiang Medicine
Note: Product cover images may vary from those shown
6 of 5

 

 

Loading
LOADING...

Adroll
adroll